Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The synthesis of LL-37 was enhanced with butyrate (a product of bacterial fermentation) and interleukin-1β (IL-1β) (a proinflammatory cytokine in colitis) in the presence of exogenously added purified MUC2.
|
28069814 |
2017 |
Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our results showed that ginsenoside Rg1 markedly reduces proinflammatory cytokines release upon DSS stimulation of mouse dendritic cells, that ginsenoside Rg1 suppresses IL-1β (Interleukin 1 beta) and TNF-α (Tumor necrosis factor alpha) release via up-regulation of NLRP12 (NACHT, LRR and PYD domains-containing protein 12) expression, and that ginsenoside Rg1 significantly decreases the inflammatory response to DSS-induced mouse colitis, as evidenced by increased body weight, reduced colonic damage scores and disease activity index (DAI), and lowered proinflammatory cytokines levels.
|
28605639 |
2017 |
Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here we further investigated the anti-inflammatory effect of compound 1 in DSS-induced colitis in C57BL/6 and NLRP3(-/-) mice, and revealed the possible modulation by compound 1 of NLRP3 inflammasome-mediated IL-1β release from macrophages.
|
26588861 |
2016 |
Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, miR-206 increased dextran sodium sulphate-induced colitis severity (i.e., increased bodyweight loss, DAI score, colon shrinkage, and MPO activity), which was partially ameliorated by miR-206-antagomir treatment. miR-206-agomir treatment potently suppressed A3AR expression and increased NF-κB signalling and downstream cytokine (TNF-α/IL-8/IL-1β) expression in the mouse colon, in contrast to miR-206-antagomir administration.
|
27893428 |
2017 |
Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Either exogenous IL-1β or IL-18 ameliorated the colitis with or without reduction in Th2 cytokine expression, respectively.
|
27966619 |
2016 |
Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Furthermore, ZFE effectively modulated the mRNA expression of redox-sensitive transcription factors, such as nuclear factor (erythroid-derived 2)-like 2 and heme oxygenase-1, downregulated the expression of p38 mitogen-activated protein kinase, and upregulated that of vascular endothelial growth factor A and interleukin-1β in AcOH-induced colitis in rats.
|
29518435 |
2018 |
Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
We showed worsened colonic inflammation in Atg16l1 deficiency mice in DSS induced murine colitis with increased proinflammatory cytokines of IL-1β and TNF-α.
|
28390705 |
2017 |
Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The clinical relevance of these findings was assessed by treating CGD patients who had severe colitis with IL-1 receptor blockade using anakinra.
|
24550444 |
2014 |
Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In this study, extracellular vesicles (EVs) from cultured medium of bone-marrow mesenchymal stem cells (BMSCs) transfected with recombinant lentiviruses can serve as a stable delivery system and overexpress miR-146a, which significantly inhibited TNF receptor-associated factor 6 (TRAF6) and IL-1 receptor-associated kinase 1 (IRAK1) expression in TNBS-induced colitis of rats.
|
30654310 |
2019 |
Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
All-trans retinoic acid cotreatment (1 mg/kg BW, i.p. daily) of DSS-treated mice (3% in drinking water for 7 days) alleviated colitis-associated weight loss, diarrheal phenotype, and induction of IL-1β and CXCL1 and a decrease in DRA mRNA and protein levels in the colon.
|
31634391 |
2020 |
Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our results show that GLP-1-SSM treatment markedly alleviated the colitis phenotype by reducing the expression of pro-inflammatory cytokine IL-1β, increasing goblet cells and preserving intestinal epithelial architecture in colitis model.
|
27553076 |
2017 |
Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Seventy-two hours following colitis induction, macroscopic and microscopic mucosal lesions, and the colonic levels of tumor necrosis factor-alpha (TNF-α) and interleukin-1β (IL-1β) were determined.
|
30318564 |
2018 |
Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
SR58611A significantly reduced the severity of colitis as well as the tissue levels of TNF-alpha, IL-1beta and IL-6.
|
18492028 |
2008 |
Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Blockade of IL-1β activity by treatment with IL-1R antagonist (IL-1Ra; Anakinra) inhibited colitis acceleration in TLR2/MDR1A double deficiency; intestinal CD11b(+)Ly6C(+)-derived IL-1β production and inflammation entirely depended on MyD88.
|
23636052 |
2013 |
Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In addition, AG inhibited the production of pro-inflammatory cytokines, such as TNF-α, IL-1β, and IL-6, and the protein expression of COX-2 and iNOS in mice with DSS-induced colitis.
|
28695925 |
2017 |
Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Intraperitoneally administered MSCs (2 × 10<sup>6</sup>) significantly reduced progression of DSS-induced colitis and reduced serum levels of inflammatory cytokines (IL-1β, IL-12, and IL-6).
|
29471245 |
2018 |
Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cytokines, specifically IL-4 and IL-1, also play an important role in the development of colitis in TCR alpha-/- mice.
|
10723681 |
2000 |
Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here, we show that ISR activation by arsenite (Ar) results in suppression of IL-1β production in macrophages and inhibition of DSS-induced colitis in a murine model through a novel posttranscriptional and translation regulatory (PTR) mechanism.
|
30578631 |
2019 |
Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
MIR301A-knockout mice were resistant to the development of colitis following administration of DSS; their colon tissues expressed lower levels of interleukin 1β (IL1β), IL6, IL8, and tumor necrosis factor than colons of control mice.
|
28193514 |
2017 |
Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
In consistence with these results, COMMD10-deficiency in Ly6C<sup>hi</sup> monocytes, but not in intestinal-resident lamina propria macrophages, led to increased IL-1β production and aggravated colonic inflammation in a model of DSS-induced colitis.
|
30487795 |
2018 |
Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
DAI evaluation, colon length, colon tissue morphology, histologic damage scores and relative protein concentrations (MPO, TNF-α and IL-1β) demonstrated that the Alg/Chi/IL-1Ra microcapsules alleviated DSS-induced colitis in mice.
|
30779979 |
2019 |
Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study was performed in rats with dinitrobenzenesulfonic acid (DNBS)-induced colitis, to investigate how the direct blockade of NLRP3 inflammasome with an irreversible inhibitor (INF39) compares with Ac-YVAD-cmk (YVAD, caspase-1 inhibitor) and anakinra (IL-1β receptor antagonist), acting downstream on NLRP3 signaling.
|
30559669 |
2018 |
Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We found that the incubation of MSCs with TNF-α and IFN-γ aggravates colitis, where high levels of pro-inflammatory factors, such as interleukin (IL)-17, IL-8, IL-12, IL-1β, transforming growth factor (TGF)-β, TNF-α and IFN-γ, were secreted.
|
31632588 |
2019 |
Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The extract showed effect in both colitis models reducing the expression of proinflammatory mediators (IL-1β, TNF-α, and iNOS), and improving the intestinal epithelial barrier integrity restoring the expression of ZO-1, MUC-2, and TFF-3.These effects were confirmed in vitro.
|
28731213 |
2017 |
Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Intravenously administered MSCs exhibited modest anti-inflammatory capacity in the acute phase of colitis by reducing IL-1β protein levels in the inflamed colon.
|
30611671 |
2019 |